Xin Zhu

Dr. Xin Zhu

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2014 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
Jing HanJing Han
Jing Han
PLPing Lv
Ping Lv
JYJiang-Liu Yu
Jiang-Liu Yu
YWYichen Wu
Yichen Wu
XZXin Zhu
Xin Zhu
ZLZhi-Qiang Ling
Zhi-Qiang Ling

14 December 2025 in Medcomm
Verified
Journal Article
Open access
WLWentao Li
Wentao Li
CCChao Chen
Chao Chen
XZXin Zhu
Xin Zhu
ZCZhang Chenping
Zhang Chenping
Complex and dynamic networks of molecules are involved in human diseases. Single‐cell and spatial multiomics approaches have created new avenues for understanding the pathogenesis and diagnosis of diseases. Cell connections and characteristics in diseases may be examined more thoroughly by integration single‐cell and spatial multiomics. In this paper, we first reviewed the single‐cell and spatial multiomics approaches. Subsequently, the use of single‐cell and spatial multiomics to comprehend the mechanisms of human diseases, such as cancer (head and neck squamous cell carcinoma), neurodegenerative diseases, and aging, was discussed. Furthermore, we outline how deep learning approaches are now being applied to single‐cell and spatial multiomics data analysis in an effort to better define the pathogenic alterations upstream and the downstream molecular effects of diseases. Particularly, single‐cell and spatial multiomics are being utilized to help guide treatment plans, evaluate risks, and determine how they can affect precision medicine. Despite the relative youth of the field, the development of single‐cell coupled with spatial multiomics promises to provide a powerful tool for elucidating the pathogenesis of diseases.

1 March 2021 in Molecular and Cellular Endocrinology
Verified
Journal Article
Open access
QWQingliang Wen
Qingliang Wen
YHYi Heqing
Yi Heqing
KYKe Yang
Ke Yang
CYChangtian Yin
Changtian Yin
WYWen-Juan Yin
Wen-Juan Yin
XZXin Zhu
Xin Zhu
In this study, we aimed to clarify the role of PIM-1 in papillary thyroid carcinoma (PTC) in vitro and investigate the relationship between PIM-1 and redox proteins (NOX4, SOD2, and GPX2) at the tissue and cellular levels. As a PIM-1 inhibitor, SGI-1776 inhibited cell proliferation, colony formation, migration and induced an increase in apoptosis and reactive oxygen species in two PTC cell lines (BCPAP and TPC-1). The expressions of PIM-1, SOD2 and GPX2 were downregulated after siNOX4 exposure. Immunohistochemistry in 120 PTC patients showed that all four proteins exhibited higher expression levels in PTC tissues than in adjacent normal tissues. PIM-1 expression was related to NOX4, SOD2, and GPX2 expressions. The Cancer Genome Atlas database analysis showed the significant correlation between the expression of NOX4 and PIM-1. Our results demonstrated that PIM-1 played an important oncogenic role in PTC carcinogenesis that may be related to oxidative stress.

10 October 2016 in Molecules
Verified
Journal Article
Open access
PDF file
NLNingning Liu
Ningning Liu
LLLailai Li
Lailai Li
XZXin Zhu
Xin Zhu
ZLZhi-Qiang Ling
Zhi-Qiang Ling
JFJianguo Feng
Jianguo Feng
Yi WangYi Wang
Yi Wang
Chronic kidney disease (CKD) is a worldwide health problem with growing prevalence in developing countries. Renal tubular epithelial-mesenchymal transition (EMT) is a critical step and key factor in the development of this condition. Renal tubulointerstitial fibrosis is a basic pathological change at the later stages of the disease. Therefore, blocking the development of EMT could be a critical factor in curing CKD. We have established a cell-based high-content screening (HCS) method to identify inhibitors of EMT in human proximal tubular epithelial (HK-2) cells by automatic acquisition and processing of dual-fluorescent labeled images. With the aid of chromatographic separation and mass spectrometry, we achieved the rapid and reliable screening of active compounds from the Chinese herbal medicine Tong-Mai-Yang-Xin-Wan (TMYX) for treating EMT. Five fractions were found to exert anti-EMT activity and were further identified by liquid chromatography coupled with tandem mass spectrometry. Glycyrrhizic acid, glyasperin A, and licorisoflavan A were found to inhibit EMT. The proposed approach was successfully applied to screen active compounds from TMYX on TGF-β1-stimulated HK-2 cells and may offer a new means for identifying lead compounds for treating EMT from registered Chinese herbal medicines.

9 September 2023 in Oncogene
Verified
Journal Article
Closed access
PDF file
WPWenting Pan
Wenting Pan
YTYihao Tian
Yihao Tian
QZQian Zheng
Qian Zheng
ZYZelin Yang
Zelin Yang
YQYulong Qiang
Yulong Qiang
FLFeng Li
Feng Li

18 May 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
JWJiaqi Wang
Jiaqi Wang
QXQianqian Xu
Qianqian Xu
ZXZiyang Xuan
Ziyang Xuan
YMYuting Mao
Yuting Mao
XTXi Tang
Xi Tang
XZXin Zhu
Xin Zhu
Objective: Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC; RAIR-DTC) have a poor prognosis. The aim of this study was to provide new insights and possibilities for the diagnosis and treatment of RAIR-DTC. Methods: The metabolomics of 24 RAIR-DTC and 18 non-radioiodine-refractory (NonRAIR) DTC patients samples were analyzed by liquid chromatograph-mass spectrometry. Cellular radioiodine uptake was detected with γ counter. Sodium iodide symporter (NIS) expression and thyroid stimulating hormone receptor (TSHR) were measured by Western blot analysis. CCK8 and colony formation assays were used to measure cellular proliferation. Scratch and transwell assays were performed to assess cell migration and invasion. Annexin V/PI staining was used to detect cell apoptosis. Cell growth in vivo was evaluated by a tumor xenograft model. The acetoacetate (AcAc) level was measured by ELISA. Pathological changes, Ki67, NIS, and TSHR expression were investigated by immunohistochemistry. Results: The metabolite profiles of RAIR could be distinguished from those of NonRAIR, with AcAc significantly lower in RAIR. The significantly different metabolic pathway was ketone body metabolism. AcAc increased NIS and TSHR expression and improved radioiodine uptake. AcAc inhibited cell proliferation, migration, and invasion, and as well promoted cell apoptosis. Ketogenic diet (KD) elevated AcAc levels and significantly suppressed tumor growth, as well as improved NIS and TSHR expression. Conclusion: Significant metabolic differences were observed between RAIR and NonRAIR, and ketone body metabolism might play an important role in RAIR-DTC. AcAc improved cellular iodine uptake and had antitumor effects for thyroid carcinoma. KD might be a new therapeutic strategy for RAIR-DTC.